{"id":"https://openalex.org/W2944282188","doi":null,"title":"Overcoming Barriers to Erythropoietic Therapy","display_name":"Overcoming Barriers to Erythropoietic Therapy","publication_year":2002,"publication_date":"2002-09-03","ids":{"openalex":"https://openalex.org/W2944282188","mag":"2944282188"},"language":"en","primary_location":{"id":"mag:2944282188","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/review-article/overcoming-barriers-erythropoietic-therapy","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080006341","display_name":"John A. Glaspy","orcid":"https://orcid.org/0000-0002-1800-9076","observed_orcids":["https://orcid.org/0000-0002-1800-9076"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"John A. Glaspy","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1800-9076","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5080006341"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4632,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.66911537,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11534","display_name":"Erythropoietin and Anemia Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-patients","display_name":"cancer patients","score":0.6740000247955322},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.6710000038146973},{"id":"https://openalex.org/keywords/darbepoetin-alfa","display_name":"darbepoetin alfa","score":0.9739999771118164},{"id":"https://openalex.org/keywords/erythropoiesis-stimulating-agents","display_name":"erythropoiesis-stimulating agents","score":0.8640000224113464},{"id":"https://openalex.org/keywords/treatment-non-response","display_name":"treatment non-response","score":0.7990000247955322},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9850000143051147},{"id":"https://openalex.org/keywords/barriers-to-treatment","display_name":"barriers to treatment","score":0.34200000762939453}],"concepts":[{"id":"https://openalex.org/C2781404941","wikidata":"https://www.wikidata.org/wiki/Q2178381","display_name":"Darbepoetin alfa","level":3,"score":0.7314184308052063},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.602571427822113},{"id":"https://openalex.org/C2776164570","wikidata":"https://www.wikidata.org/wiki/Q5383794","display_name":"Epoetin alfa","level":3,"score":0.46650925278663635},{"id":"https://openalex.org/C2983331546","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer therapy","level":3,"score":0.45847088098526},{"id":"https://openalex.org/C148220186","wikidata":"https://www.wikidata.org/wiki/Q7111912","display_name":"Outcome (game theory)","level":2,"score":0.4533904194831848},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4405198097229004},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36785465478897095},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23297548294067383},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.1238526999950409},{"id":"https://openalex.org/C144237770","wikidata":"https://www.wikidata.org/wiki/Q747534","display_name":"Mathematical economics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2944282188","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/review-article/overcoming-barriers-erythropoietic-therapy","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2418270769","https://openalex.org/W2156285271","https://openalex.org/W2071680060","https://openalex.org/W2030435913","https://openalex.org/W2345313920","https://openalex.org/W2137896763","https://openalex.org/W2036971961","https://openalex.org/W2319347477","https://openalex.org/W2588808794","https://openalex.org/W2164023074"],"abstract_inverted_index":{"Barriers":[0],"to":[1,28],"use":[2],"of":[3,17,26],"erythropoietic":[4,33],"therapy":[5],"in":[6,11],"cancer":[7],"patients":[8],"include":[9],"nonresponse":[10],"a":[12],"sizable":[13],"proportion,":[14],"resultant":[15],"lowering":[16],"cost-effectiveness,":[18],"and":[19],"inconvenience.":[20],"Darbepoetin":[21],"alfa":[22],"represents":[23],"the":[24],"outcome":[25],"efforts":[27],"develop":[29],"agents":[30],"with":[31],"improved":[32],"potency.":[34]},"counts_by_year":[],"updated_date":"2025-11-06T04:12:42.849631","created_date":"2019-05-16T00:00:00"}